Abstract

The present disclosure provides for compounds including derivatives of haloperidol, pharmaceutical compositions including haloperidol derivatives, methods of use of the haloperidol derivatives and their pharmaceutical compositions, and the like. Compounds and pharmaceutical compositions of the present disclosure can be used in combination with one or more therapeutic agents for treating inflammatory arthritis, gout, or other inflammation-related diseases or conditions.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/33 - Heterocyclic compounds

Abstract

An insulin delivery supervisor (IDS) with a safety analysis and supervision function that can reside between the insulin request and the insulin delivery and can intercept any excessive insulin requests before the insulin was delivered. The IDS can be implemented in any system based on insulin pump or pen and will work with either SMBG or CGM modes of blood glucose monitoring.

IPC Classes  ?

• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
• G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones

Abstract

The present disclosure provides for methods and systems for processing brine to obtain lithium. The present disclosure provides for methods that leverages intercalation materials and drives lithium capture using a chemical approach to treating brine as opposed an electrochemical approach, which can be complicated and expensive. The present disclosure provides for a chemical redox-driven approach to selectively extract Li+ from brine.

IPC Classes  ?

• C01D 15/02 - OxidesHydroxides
• C01D 15/04 - Halides
• C01D 15/06 - SulfatesSulfites
• C01D 15/10 - Nitrates

Abstract

ii = 82 nM, 122-fold SphK2 selective) with validated in vivo activity. Modifications to the guanidine head of the inhibitor provided compounds that were effective in alleviating the observed poor oral bioavailability.

IPC Classes  ?

• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 37/02 - Immunomodulators

Abstract

Provided are methods for treating viral infections in subject in need thereof. In some embodiments, the method include administering to the subject a composition that has an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike. Also provided are compositions that include an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike, which compositions can optionally be employed in the disclosed methods.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

Provided are methods and compositions for treating and/or preventing C. difficile infections, particularly recurring C. difficile infections. The compositions for use in treating and/or preventing C. difficile infections include in some embodiments at least one agent that inhibits an alpha 2 adrenergic receptor, and the presently disclosed methods include administering at least one such composition to a subject in need thereof, optionally in combination with other therapeutically active agents including but not limited to an enhancer of an IL-13 biological activity, optionally an IL-13 peptide or a fragment or homolog thereof; an interleukin-13 receptor subunit alpha-2 (IL-13Ra2) inhibitor; an enhancer of an Interleukin-33 (IL-33) biological activity, optionally an IL-33 polypeptide or a biologically active fragment or homolog thereof; or any combination thereof.

IPC Classes  ?

• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 38/14 - Peptides containing saccharide radicalsDerivatives thereof
• A61K 38/20 - Interleukins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/04 - Antibacterial agents

Abstract

Compositions and methods for regenerating pancreatic islet viability and/or cell proliferation in vitro, ex vivo, and/or in vivo; and/or for regenerating glucose-stimulated insulin secretion; and/or for regenerating viability and/or cell proliferation of a transplanted pancreatic islets; and/or for preventing and/or inhibiting rejection of a transplanted islets; and/or for pancreatic islet transplantation; and/or for treating a symptom of a condition, disorder, or disease associated with abnormal insulin responsiveness to glucose are provided. In some embodiments, the compositions include a peptide and/or a pharmaceutically acceptable salt thereof, and/or a biologically active fragment, analog, or derivative thereof, wherein the peptide, the pharmaceutically acceptable salt thereof, and/or the biologically active fragment, analog, or derivative thereof has an amino acid sequence of any of SEQ ID NOs: 1-60, or any combination thereof.

IPC Classes  ?

• A61K 38/26 - Glucagons
• A61K 35/39 - PancreasIslets of Langerhans

Abstract

Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods include administration of combinations of agents, including combinations that include dupilumab. The methods can be used to treat subjects diagnosed with a SARS-CoV-2 infection, including those already hospitalized to treat COVID-19 and/or those also having lymphopenia, to reduce the severity of outcomes related to COVID-19, such as admittance to the intensive care unit (ICU), mechanical ventilation, and/or death, particularly over periods of time longer than a month or two months following the initial administration of the agents. Compositions for use in the treatment of COVID-19 are also described.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Various technological aspects of functional tremor retrainment are described. For example, a mobile device may measure a baseline tremor frequency, determine a cue frequency based on the baseline tremor frequency, provide motion cues at the cue frequency, measure a motion frequency while providing the motion cues, and provide a feedback signal indicative of a synchrony of the motion frequency to the cue frequency.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A63B 24/00 - Electric or electronic controls for exercising apparatus of groups
• A63B 71/06 - Indicating or scoring devices for games or players

Abstract

An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

The present invention provides, among other things, compositions and methods for prophylaxis and treatment of autoimmune disease. The present invention provides, in part, bifunctional proteins comprising interleukin-2 (IL-2) and interleukin-33 (IL-33) variants having increased manufacturability and activity, which synergistically expand or stimulate tissue targeting or reparative regulatory T cells. The present invention provides compositions and methods for proliferation and activity of ST24+ regulatory T cells.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

Provided herein are methods and compositions for detecting protein biomarkers indicative of type 1 or type 2 diabetes.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

The present invention provides, among other tilings, improved interleukin-33 (IL-33) variants engineered for increased manufacturability and activity, for example, mutated at one or more of N60, C116, C97, C121 or C148 relative to a truncated IL-33. The present invention also provides a. multifunctional fusion protein comprising an IL-33 variant associated with an IL-2 polypeptide and optionally, a half-life extension moiety. The present invention further provides compositions and methods for proliferation and activity of ST2+ regulatory T cells, for prophylaxis and treatment of autoimmune disease.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]

Abstract

The present invention provides, among other things, compositions and methods for prophylaxis and treatment of cancer and other diseases. The present invention provides, in part, a bifunctional protein comprising an IL-2 variant biased to IL-2Rβ, and an interleukin- 33 (IL-33) variant engineered for increased activity and/or manufacturability. The present invention, for example, provides IL-2 variants mutated at one or more of F42, L80, R81, L85, 186 or 192 relative to wild-type IL-2 associated with IL-33 variants mutated at one or more of N60, Cl 16, C97, C121 or CMS relative to a truncated IL-33, that preferentially expands T effector cells. The present invention, among other things, provides a bifunctional fusion protein, optionally linking an IL-2 variant biased to IL-2Rβ, and an interleukin-33 (IL-33) variant via a linker, that preferentially expands T effector cells.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]
• C07K 14/55 - IL-2

Abstract

Apparatus and techniques described herein can include or use a rotationally-driven microfluidic assembly. For example, a sample can be propelled to a sample recovery chamber from a sample chamber using a gas evolved from a reaction between the liquid reagent and a dry reagent. Such gas evolution can provide displacement of a sample liquid or other liquid in an inward direction, such as proximally toward a center of rotation. Such gas evolution can include features or reagents, or both, that are compatible with downstream nucleic acid amplification tests.

IPC Classes  ?

• C12Q 1/6844 - Nucleic acid amplification reactions
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The present disclosure provides for hybrid catalysts, methods of converting CO2 to C2 products (e.g., ethylene), systems for converting CO2 to C2 products (e.g., ethylene), and the like. The hybrid catalyst of the present disclosure effectively uses two steps of converting CO2 to ethylene in a single hybrid catalyst.

IPC Classes  ?

• C07C 1/12 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon dioxide with hydrogen
• B01J 23/72 - Copper
• B01J 27/24 - Nitrogen compounds
• B01J 35/45 - Nanoparticles
• B01J 37/04 - Mixing

Abstract

A method can include receiving a biological sample including the target cells, e.g., at an inlet of a microfluidic structure. This can involve flowing the target cells, e.g., suspended in a first buffer, at a first flow rate within a main channel of the microfluidic structure. At least one focusing flow can be applied to the biological sample, using a second buffer at a second flow rate, to help establish a boundary defining a central region or streamline. The central region can contain the target cells within the main channel and promote ion diffusion between the first and second buffers.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

SLC2A11-MIFSLC2A11-MIF was identified that is present in nearly 50% of CRC samples but absent in non-cancer colon tissue. Disclosed herein is a method for diagnosing and treating cancers expressing this chimeric RNA and protein.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12N 5/0784 - Dendritic cellsProgenitors thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts
• C12N 15/86 - Viral vectors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

in vivoin vivo.

IPC Classes  ?

• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/35 - Cytokines
• A61K 40/36 - Immune checkpoint inhibitors
• A61K 40/42 - Cancer antigens

Abstract

Provided are a method, system, and computer-readable medium for personalizing titration measurement for basal insulin dosing. The personalization can be achieved using spare self-monitoring blood glucose (SMBG) and/or dense continuous glucose monitoring (CGM) data to predict a fasting blood glucose (FBG) envelope accounting for online estimation of titration noise representative of variability in daily fasting measurement. As a result, basal insulin dosing directed to causing the FBG envelope to be maintained for an optimal glycemic range can then be obtained.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
• G01N 33/66 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood sugars, e.g. galactose
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection

Abstract

Electrophilic purine-based compounds comprising mono- and di-halo-substituted purine moieties are described. The compounds also include acetamide substituents. The compounds are reactive in nucleophilic aromatic substitution reactions. The compounds generally showed the highest reactivity when a thiol was used as the nucleophile. Methods of using the compounds to covalently modify proteins containing nucleophilic side chains and/or to modulate protein activity are also described.

IPC Classes  ?

• C07D 473/40 - Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
• A61K 31/52 - Purines, e.g. adenine
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are compositions that include compositions of galactosyl -conjugated lipid nanoparticles (LNPs) encapsulating one or more active agents. In some embodiments, the galactosyl- conjugated LNPs have a lipid component having D-Lin~MC3-DMA, ALC-0315 and. SM-102, cholesterol, DSPC and DOPE, and DMG-2000-PEG. In some embodiments, the GalNAc-conjugated LNP has one or more galactosyl moieties bioconjugated to cholesterol present with a lipid component of the GalNAc -conjugated LNP. Also provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated, with undesirable PCSK9 gene expression, optionally a cardiovascular disease, disorder, or condition, including but not limited, to atherosclerosis and/or thrombosis, and sepsis, septic shock, cytokine storm, or sequelae thereof.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Systems and methods are provided for estimating immune response effected by patient specific and plan specific radiation treatments (such as, e.g., SBRT). The systems and methods may take into account radiation impact on circulating immune blood cell types or sub-types, such as T lymphocytes, B lymphocytes, natural killer cells, erythrocytes, and/or neutrophils, and predict time dependent fractional blood count and cell kill following radiation therapy treatment. Additionally, the system, method, and computer readable medium provide parameters such as a dose dependent lymphocyte kill function and average net release rate of new lymphocytes into circulating blood (including promotion of cytotoxic T cells and suppression of lymphocytes in blood), which may be used for optimization of RT treatment plans.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

Various aspects of the instant disclosure provide a metal-organic framework- polymer composite organic-gel material. The material includes zirconium -based MOF (UiO-66) and multiple polymer components to form a gel network and exhibit multifunctionality (conductivity and piezoelectricity).

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• C07F 7/00 - Compounds containing elements of Groups 4 or 14 of the Periodic Table
• C08G 83/00 - Macromolecular compounds not provided for in groups
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Abstract

The present disclosure provides for electrodes, batteries that include the electrodes, method of making electrodes and the like. The present disclosure provides for electrodes that are thicker than typical electrodes that have a higher energy density at the cell level, regardless of the specific cell chemistry. The electrodes are all active material (AAM) electrodes (e.g., AAM anodes and AAM cathodes). In an aspect, the electrodes of the present disclosure have improved ion transport in the electrode microstructure and the concomitant reduced tortuosity and improved retention of electrochemical capacity at increased cycling rates.

IPC Classes  ?

• H01M 10/056 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes
• H01G 11/24 - Electrodes characterised by structural features of the materials making up or comprised in the electrodes, e.g. form, surface area or porosityElectrodes characterised by the structural features of powders or particles used therefor
• H01G 11/60 - Liquid electrolytes characterised by the solvent
• H01G 11/62 - Liquid electrolytes characterised by the solute, e.g. salts, anions or cations therein
• H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
• H01M 10/058 - Construction or manufacture
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy

Abstract

Described herein are systems, methods, and computer readable medium for, among other things, predictive platforms for novel microbial therapeutics. Such systems, methods, and computer readable medium can be utilized for identifying candidate therapeutics and/microbiota for administration against a candidate bacterial infection in particular. In embodiment, the bacterial infection is bacterial vaginosis. An aspect of the present disclosure also provides a system, method and computer readable medium for, among other things, algorithms/models that enabled the predictions of the specific combinations of bacteria and putative therapeutic targets to enable the therapeutic intervention.

IPC Classes  ?

• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16B 40/30 - Unsupervised data analysis
• C12Q 1/6869 - Methods for sequencing

Abstract

Provided are biomarkers for parenteral nutrition associated cholestasis (PNAC) in subjects, especially infants receiving parenteral nutrition (PN). Using such biomarkers provide methods of diagnosing and/or assessing risk of PNAC in a subject, including screening a sample from a subject believed to be at risk for PNAC for one or more biomarkers of PNAC. The biomarkers can include one or more fecal metabolites. Such biomarkers and associated methods provide neonatal intensive care unit clinicians with an additional tool for early identification of PNAC risk. Early identification of high-risk infants would enable clinicians to confidently optimize caloric nutrition with PN for infants at low risk of developing PNAC and enable proactive mitigation with alterations to the administered PN.

IPC Classes  ?

• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

Low power radio frequency (RF) receivers and related circuits are described.

IPC Classes  ?

• H03F 1/02 - Modifications of amplifiers to raise the efficiency, e.g. gliding Class A stages, use of an auxiliary oscillation
• H03F 3/19 - High-frequency amplifiers, e.g. radio frequency amplifiers with semiconductor devices only
• H04B 1/16 - Circuits

Abstract

In one aspect, the disclosure relates to an apparatus comprising: a plate; a plurality of wells set into the plate, wherein each individual well of the plurality of wells extends from an outer surface of the plate to an inner surface of the individual well; and a plurality of hydrogels, wherein at least two individual wells of the plurality of wells each comprise a singular hydrogel of the plurality of hydrogels; wherein each individual hydrogel of the plurality of hydrogels comprises a dithiol crosslinker and a first backbone polymer functionalized with an alkene; and wherein at least one hydrogel of the plurality of hydrogels is different from the remaining hydrogels of the plurality of hydrogels. Also disclosed herein are methods of fabricating the apparatus. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the disclosure.

IPC Classes  ?

• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• C12M 1/18 - Multiple fields or compartments
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• C08J 3/075 - Macromolecular gels
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

Disclosed are various approaches for bit-serial computing embedded in the DRAM subarray, leveraging the massive parallelism of DRAM row operations. The present disclosure discloses digital techniques that can outperform analog charge-sharing techniques. Digital techniques can use more area but support a wider range of computing primitives, and allow a sequence of logic operations to be performed at higher clock speeds, be-tween slower subarray row reads/writes. The present disclosure describes a range of bit-serial architectures, and evaluate raw performance as well as area and energy efficiency. Results show that the digital architecture demonstrates 20× speedup over CPU, 5× over GPU, and 1.7× over SIMDRAM, an analog architecture.

IPC Classes  ?

• G06F 9/30 - Arrangements for executing machine instructions, e.g. instruction decode
• G06F 9/38 - Concurrent instruction execution, e.g. pipeline or look ahead

Abstract

Systems and methods of generating music that encodes personalized information implement and/or include generating a personalized sonification model based on music modeling data pertaining to a user; receiving physiological data pertaining to the user, wherein the physiological data is related to at least one of a physical wellness or a behavioral wellness of the user; generating a melody, wherein the melody encodes a wellness information or modification based on the personalized sonification model and the physiological data; and providing the melody to the user to convey the wellness information or modification.

IPC Classes  ?

• G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation

Abstract

The capillary transfer technology presented here represents a powerful approach to transfer soft films from surface of liquid onto a solid substrate in a fast and defect-free manner. The fundamental theoretical model and transfer criteria validated with comprehensive experiments and finite element analyses, for the first time provides a quantitative guide and optimization for the choice of material systems, operating conditions and environments for scalable on-demand transfers with high yield. The intrinsically moderate capillary transfer force and externally selectable transfer direction offer robust capabilities for achieving deterministic assembly and surface properties of structures with complex layouts and patterns for potentially broad applications in the fabrication of flexible/stretchable electronics, surface wetting structures and optical devices. Integration of this technology with other advanced manufacturing technologies associated with material self-assembly, growth and layout alignment represents promising future topics and would help create emerging new manufacturing technologies that leverage unique fluidity of liquid environments.

IPC Classes  ?

• H05K 3/20 - Apparatus or processes for manufacturing printed circuits in which conductive material is applied to the insulating support in such a manner as to form the desired conductive pattern by affixing prefabricated conductor pattern
• B44C 1/175 - Transfer using solvent

Abstract

Provided are embodiments of a device, having a device body suitable to hold a syringe. The device body can have an elongated member with a distal support and a proximal support. The device further includes a ratcheting rod configured to fit moveably within an open chamber in the elongated member, where the ratcheting rod has a proximal end configured to connect to a plunger of the syringe. The device can include a lever handle hingedly connected to a distal end of the device body, and a ratcheting lever hingedly connected to a distal end of the lever handle and positioned to interact with the ratcheting rod. Compression of the lever handle forces the ratcheting lever to extend the ratcheting rod in a proximal direction and to extract the plunger of the syringe.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

(1-x)x(2-y)(2-y) (1) where M is zirconium, cerium, aluminum, silicon, lanthanum, yttrium, strontium, gadolinum, strontium, gallium, calcium, magnesium, or a combination thereof; where x is 0.05 to 0.95 and where the mixed metal oxide film is formed in the presence of a plasma; where the plasma is formed in an atmosphere that comprises nitrogen and oxygen in a molar ratio of 0.5:1 to 10:1; and where y is 0 to 0.5.

IPC Classes  ?

• C01G 27/02 - Oxides
• H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
• H01L 21/28 - Manufacture of electrodes on semiconductor bodies using processes or apparatus not provided for in groups
• H01L 21/314 - Inorganic layers
• H01L 21/336 - Field-effect transistors with an insulated gate
• H01G 4/10 - Metal-oxide dielectrics

Abstract

The present disclosure provides for graphene hybrid materials, methods of making graphene hybrid materials, batteries, methods of making batteries, methods of using batteries, shielding including the graphene hybrid materials, and the like. In an aspect, the graphene hybrid material is a carbon nanotube/graphene hybrid material, where the carbon nanotubes are grown on the surface of the graphene.

IPC Classes  ?

• C01B 32/15 - Nanosized carbon materials
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• H01G 11/36 - Nanostructures, e.g. nanofibres, nanotubes or fullerenes
• C01B 32/158 - Carbon nanotubes
• C01B 32/182 - Graphene

Abstract

dd(t)). The processor can determine a glucose rate of change (G'(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G'(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.

IPC Classes  ?

• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• A61M 5/142 - Pressure infusion, e.g. using pumps
• G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric
• G05B 13/04 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric involving the use of models or simulators

Abstract

Provided herein are methods and compositions to enhance or activate protective microglial activities (such as phagocytosis of neurotoxic material) by activating CARD9.

IPC Classes  ?

• A61K 31/716 - Glucans
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

Disclosed herein is a biosensor fusion protein comprising an N-terminal half of a human liver fatty acid binding protein (hLFABP) and a C-terminal half of the hLFABP separated by a circularly permuted fluorescent protein (cpFP), wherein the binding of the N-terminal half of the hLFABP and the C-terminal half of the of the hLFABP to a per- or polyfluoroalkyl substance (PFAS) elicits a change in fluorescence of the cpFP. Also disclosed method for detecting per- and polyfluoroalkyl substances (PFAS) in a sample, comprising contacting the sample with the biosensor disclosed herein, assaying the sample for fluorescence, wherein an increase in fluorescence is an indication of the presence of PFAS. In some embodiments, the PFAS is perfluorooctanoic acid (PFOA). In some embodiments, the sample is a water sample.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 21/64 - FluorescencePhosphorescence
• G01N 27/327 - Biochemical electrodes

Abstract

The present disclosure provides for double-network hydrogel particles, methods of making double-network hydrogel particles, methods of making objects (e.g., three-dimensional objects) using double-network hydrogel particle, and the like. In an aspect, double-network hydrogel particles are viscoelastic voxels (e.g., spherical or semi-spherical) that can be precisely manipulated in three-dimensional space and can be used in both soft matter science and biomanufacturing. The present disclosure provides for a voxelated bioprinting technology that enables the digital assembly of interpenetrating double-network hydrogel particles to form objects, in particular three-dimensional objects.

IPC Classes  ?

• A61L 27/52 - Hydrogels or hydrocolloids
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
• A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 70/00 - Materials specially adapted for additive manufacturing

Abstract

The present disclosure presents systems and methods for implementing a quantum error correction code with quantum light. One such method comprises iteratively training, by a computing system using reinforcement learning, at least one neural network that is interacting with a model of a measurement-based quantum optical circuit to generate circuit parameters for the measurement-based quantum optical circuit, wherein the generated circuit parameters produce a target optical quantum state of the measurement-based quantum optical circuit; applying the generated circuit parameters to the measurement-based quantum optical circuit; and/or outputting a quantum state of the measurement-based quantum optical circuit.

IPC Classes  ?

• G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation
• H03M 13/00 - Coding, decoding or code conversion, for error detection or error correctionCoding theory basic assumptionsCoding boundsError probability evaluation methodsChannel modelsSimulation or testing of codes
• G06F 11/08 - Error detection or correction by redundancy in data representation, e.g. by using checking codes
• G06N 20/00 - Machine learning
• G06N 10/00 - Quantum computing, i.e. information processing based on quantum-mechanical phenomena

Abstract

Embodiments can relate to an insulin delivery controller which implements a processor configuration to efficiently attain an insulin delivery target. The insulin delivery controller can include a processor and a memory associated with the processor. The processor can process glucose data received from the memory, including a data representation of glycemic disturbance (d(t)). The processor can determine a glucose rate of change (G′(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G′(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.

IPC Classes  ?

• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection

Abstract

Provided are methods for treating subjects with coronavirus infections. The methods include providing a subject infected with a coronavirus resulting in a prothrombotic condition in addition to being infected by a coronavirus, and administering to the subject an angiotensin (1-7) peptide or an analog or derivative thereof, a Mas Receptor (MasR) agonist, or any combination thereof. The subject may be suffering from COVID-19 disease, including but not limited to a thrombotic complication, an adverse pregnancy outcome, and/or a complication resulting from an underlying prothrombotic state. Also provided are compositions that include Ang (1-7) peptides, analogs, and/or derivatives thereof that are associated with degradable and/or non-degradable polymers having electrostatic interactions therewith, hydrophobic interaction therewith, hydrogen bonding interactions therewith, or any combination thereof. Also provided are uses of Ang (1-7) peptides, analogs, and/or derivatives thereof and/or a Mas Receptor (MasR) agonists for treating subjects infected with coronaviruses and/or for preparing medicaments therefore.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present application discloses a novel fusion peptide of IL-2 and IL-33 and its use. It comprises a biologically active domain of Interleukin-2 (IL-2) or a biologically active fragment or homolog thereof, and a biologically active domain of Interleukin-33 (IL-33) or a biologically active fragment or homolog thereof. The two portions can be linked by a linker sequence. The application discloses that combination therapies using IL-2 and IL-33 or a therapy using the IL233 fusion protein are effective in preventing or treating diseases and disorders such as autoimmune diseases and disorders, inflammation, etc. Depending on the subject's disease or disorder, the compositions of the invention are useful for preventing certain symptoms, treating the disease, and alleviating at least some of the symptoms.

IPC Classes  ?

• C07K 14/55 - IL-2
• A61K 38/00 - Medicinal preparations containing peptides
• C07K 14/54 - Interleukins [IL]

Abstract

The present disclosure presents systems and related methods of programming with concepts. One such method comprises implementing, by a computing device, at least one concept of an application as a full-stack concept codebase, wherein syntax and semantics of the concept codebase are generated using an available programming language; organizing, by the computing device, concept codebases into one or more codebase directories; and/or composing, by the computing device, a plurality of concept codebases from the one or more codebase directories into a larger concept codebase using composition operators to build a complete concept-based full-stack application system.

IPC Classes  ?

• G06F 8/30 - Creation or generation of source code
• G06F 8/00 - Arrangements for software engineering

Abstract

Embodiments relate to a system for processing glucose data by efficient glucose database management. The system includes a physical data store containing glucose measurement data and a representation for at least one cluster of the glucose measurement data, wherein the representation approximates a glycemic profile vector array for a cluster of multiple glucose profiles segmented by plural time ranges. The system includes a processor and computer memory configured with instructions stored thereon that when executed will cause the processor to: 1) receive glucose measurements; 2) convert the glucose measurements into vectorial form; 3) search the physical data store by comparing a newly received glucose measurement to a centroid of a cluster using a similarity metric; 3) classify the newly received glucose measurement with a cluster having a matched similarity metric based on the comparing; and 4) ascribe a treatment to the newly received glucose measurement.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Optical inspection systems, methods, and media are configured to perform and/or implement, for a plurality of image frames of a target object captured by an image sensor, the target object including at least one fiducial marker: receiving a respective image frame, the image frame including an n-dimensional array of pixel values corresponding to a plurality of colors, converting the image frame to a color-adjusted image, the color-adjusted image including a two-dimensional array of pixel values corresponding to a first color of the plurality of colors, and determining at least one centroid corresponding to at least one region in the color-adjusted image tracking the at least one centroid across at least two of the plurality of image frames; and outputting an indication of a mechanical parameter of the target object based on the tracking.

IPC Classes  ?

• G01B 11/16 - Measuring arrangements characterised by the use of optical techniques for measuring the deformation in a solid, e.g. optical strain gauge
• G06T 7/32 - Determination of transform parameters for the alignment of images, i.e. image registration using correlation-based methods
• G01N 21/88 - Investigating the presence of flaws, defects or contamination
• G03F 1/84 - Inspecting
• G01B 11/00 - Measuring arrangements characterised by the use of optical techniques

Abstract

Optical inspection systems, methods, and media are configured to perform and/or implement receiving a time series of 3D point cloud images of a target object from an imaging system, wherein the 3D point cloud images include first directional position data, second directional position data, and change in first directional velocity data; applying a self-supervised machine learning model to the time series of 3D point cloud images, wherein the trained machine learning model has been trained on a plurality of training point cloud images to which simulated cracks have been added; and identifying a mechanical failure in the target object based on an output of the machine learning model.

IPC Classes  ?

• G01N 21/88 - Investigating the presence of flaws, defects or contamination
• G03F 1/84 - Inspecting
• G06N 20/00 - Machine learning
• G06N 3/08 - Learning methods
• G01B 11/00 - Measuring arrangements characterised by the use of optical techniques

Abstract

Methods are disclosed for generating, manipulating, and controlling non-Gaussian quantum states in continuous variable cluster quantum states usable for quantum computing. Some methods can be used to generate, transport, and enlarge Schrödinger-Cat states embedded in the CV cluster quantum state. Some methods can be used to transform Schrödinger-Cat states embedded in the CV quantum cluster state to grid states (such as Gottesman-Kitaev-Preskill states) and enlarge the grid states. In certain embodiments, some of the methods may be used to generate and control non-Gaussian states in macronode cluster quantum states such as cluster states comprising two-mode macronodes.

IPC Classes  ?

• G06N 10/60 - Quantum algorithms, e.g. based on quantum optimisation, or quantum Fourier or Hadamard transforms
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

The present disclosure relates to compounds, pharmaceutical compositions, and methods of using the compounds and compositions to image reactive oxygen and nitrogen species (RONS). The disclosed compounds and pharmaceutical compositions can also be useful in treating diseases or disorders due to oxidative stress or otherwise based on RONS pathophysiology such as, for example, neurological diseases, cancer, cardiovascular diseases, and ischemia reperfusion injury (IRI). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• C07D 231/18 - One oxygen or sulfur atom

Abstract

A system and method of forming an article include floating a pliable material onto a liquid held in a bath structure and placing a curvilinear substrate into the bath structure with the substrate having at least clockwise and counterclockwise rotational degrees of freedom, relative to a lengthwise axis of the substrate, within the liquid. A lateral edge of the pliable material is in contact with an outer surface of the curvilinear substrate to define a transfer front at an intersection of the lateral edge and the curvilinear substrate, and rotation of the curvilinear substrate advances a leading longitudinal edge of the pliable material onto the curvilinear substrate from the transfer front at an initial orientation angle, alpha (α), and an advanced orientation angle, beta (β), relative to the transfer front.

IPC Classes  ?

• B29C 53/56 - Winding and joining, e.g. winding spirally
• B29C 53/04 - Bending or folding of plates or sheets
• B29C 53/08 - Bending or folding of tubes
• B29C 53/12 - Bending or folding helically, e.g. for making springs
• B29C 53/40 - Bending and joining, e.g. for making hollow articles by bending sheets or strips at right angles to the longitudinal axis of the article being formed and joining the edges for articles of definite length, i.e. discrete articles
• B21C 37/12 - Making tubes or metal hoses with helically arranged seams
• B29C 53/54 - Guiding, aligning or shaping edges
• D01D 5/02 - Starting the formation
• D01D 5/08 - Melt-spinning methods
• D01D 5/14 - Stretch-spinning methods with flowing liquid stretching media
• D01D 5/18 - Formation of filaments, threads, or the like by means of rotating spinnerets
• D02G 1/06 - Spindles

Abstract

A structure, method, and computer program product for a diabetes control system provides, but is not limited thereto, the following: open-loop or closed-loop control of diabetes that adapts to individual physiologic characteristics and to the behavioral profile of each person. An exemplary aspect to this adaptation is biosystem (patient or subject) observation and modular control. Consequently, established is the fundamental architecture and the principal components for a modular system, which may include algorithmic observers of patients' behavior and metabolic state, as well as interacting control modules responsible for basal rate, insulin boluses, and hypoglycemia prevention.

IPC Classes  ?

• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

The present disclosure provides for foldable bottlebrush polymers, foldable bottlebrush polymer networks and methods of making foldable bottlebrush polymers and foldable bottlebrush polymer networks. The present disclosure provides a general method for decoupling stiffness and extensibility of polymer networks. Instead of using classical linear polymers as network strands, an aspect of the present disclosure provides for methods using foldable bottlebrush polymers, which feature a collapsed backbone grafted with many linear side chains. Upon elongation, the collapsed backbone unfolds to release stored length, enabling remarkable extensibility. By contrast, the network elastic modulus is inversely proportional to the network strand mass and is determined by the side chains.

IPC Classes  ?

• C08F 290/04 - Polymers provided for in subclasses or
• C08F 290/06 - Polymers provided for in subclass
• C08F 290/02 - Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups on to polymers modified by introduction of unsaturated end groups

Abstract

Clostridioides difficilediff diffdiffdiff.

IPC Classes  ?

• A61K 35/74 - Bacteria
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Various examples are provided related to generating a map of an environment. In one example, a method includes obtaining a coarse global mapping of an environmental space; determining a robotic traversal path within the environmental space using the coarse global mapping, the robotic traversal path maintaining a targeted distance to a nearest structure within the environmental space; initiating traversal of a robot along the determined robotic traversal path, the robot obtaining depth sensor measurements of the nearest structure during traversal along the determined robotic traversal path; and refining the robotic traversal path during traversal by the robot along the determined robotic traversal path based upon the depth sensor measurements, where the robotic traversal path is refined online to achieve targeted resolution and local accuracy of the depth sensor measurements. A refined map of the environmental space can be generated using the depth sensor measurements.

IPC Classes  ?

• G05D 1/246 - Arrangements for determining position or orientation using environment maps, e.g. simultaneous localisation and mapping [SLAM]
• G05D 111/10 - Optical signals
• G06T 7/521 - Depth or shape recovery from laser ranging, e.g. using interferometryDepth or shape recovery from the projection of structured light

Abstract

A fully autonomous self-powered system-on-chip (SoC) that can be distributed along a fiber strand, capable of simultaneously harvesting energy, cooperatively scaling performance, sharing power, and booting-up with other SoCs in-fiber. In some examples, a system includes at least one textile fiber comprising an embedded electrical bus. The system includes a number of SoCs electrically coupled by the embedded electrical bus. Each SoC comprises at least one processor and an energy harvesting and power management unit (EHPMU) configured for power sharing and cooperative dynamic voltage and frequency scaling (DVFS) with the other SoCs.

IPC Classes  ?

• G06F 1/3203 - Power management, i.e. event-based initiation of a power-saving mode
• A41D 1/00 - Garments
• G06F 1/3206 - Monitoring of events, devices or parameters that trigger a change in power modality

Abstract

Disclosed are various embodiments for validating crowdsourced flood images using machine learning and real-time weather data. Various embodiments can obtain a weather event upload request from a client device that includes an upload geolocation and an image. Various embodiments can direct a convolutional neural network (CNN) model to predict flood activity within the image. Next, various embodiments can obtain weather data corresponding the upload geolocation from a weather application programming interface (weather API). When various embodiments determine that the weather data indicates flood conditions for the upload geolocation, various embodiments can publish the image and the upload geolocation into a plurality of flood activity images for the upload geolocation.

IPC Classes  ?

• G01C 21/36 - Input/output arrangements for on-board computers
• H04W 4/00 - Services specially adapted for wireless communication networksFacilities therefor
• G01C 11/00 - Photogrammetry or videogrammetry, e.g. stereogrammetryPhotographic surveying

Abstract

gfff) that can be combined with aerodynamic rotor power to drive the electrical generator.

IPC Classes  ?

• F03D 9/17 - Combinations of wind motors with apparatus storing energy storing energy in pressurised fluids
• F03D 9/25 - Wind motors characterised by the driven apparatus the apparatus being an electrical generator
• F03D 80/80 - Arrangement of components within nacelles or towers

Abstract

The present disclosure is directed an air-liquid-interface culture apparatus including a porous support and a polyacrylamide hydrogel layer. The porous support includes a polymer plate having a plurality of pores and a support surface. The polyacrylamide hydrogel layer is deposited onto the support surface of the porous support. The polyacrylamide hydrogel layer includes a polyacrylamide hydrogel having mechanical properties that mimic the extracellular matrix for epithelial cells in the human airway. An air-liquid-interface cell culture system disclosed herein may include the air-liquid-interface culture apparatus disclosed herein with one or more cells deposited on the polyacrylamide hydrogel layer.

IPC Classes  ?

• C08J 3/075 - Macromolecular gels
• C08F 2/48 - Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
• C08F 220/56 - AcrylamideMethacrylamide
• C08K 5/00 - Use of organic ingredients
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

A method of forming a lanthanide or transition metal doped metal halide perovskite material whereby the method includes combining a monovalent metal cation-halide compound, a divalent metal cation-halide compound, and a lanthanide or transition metal halide compound in a solvent; evaporating the solvent to form a powder; and annealing the powder to form the lanthanide or transition metal doped metal halide perovskite material. The resultant materials or devices may be applied to various industrial applications or implemented as a scintillator and applied to various industrial applications.

IPC Classes  ?

• C09K 11/77 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing rare earth metals
• C01G 21/00 - Compounds of lead
• G01T 1/20 - Measuring radiation intensity with scintillation detectors
• G01T 1/202 - Measuring radiation intensity with scintillation detectors the detector being a crystal

Abstract

Systems and techniques for compressed air energy storage and regeneration thereof are described herein. A compressor for compressed air energy storage and regeneration thereof can include a housing, a actuator, and a heat exchanger. The housing can define a volume. The actuator can be operable to expand the volume and compress the volume. The heat exchanger can be located at least partially within the housing. The heat exchanger can be configured to compress when the actuator compresses the volume, expand when the actuator expands the volume, and transfer heat with a working fluid.

IPC Classes  ?

• F17C 5/06 - Methods or apparatus for filling pressure vessels with liquefied, solidified, or compressed gases for filling with compressed gases
• F17B 1/10 - Guiding moving parts
• F17B 1/12 - Gas admission or discharge arrangements
• F17B 1/26 - Gas-holders of variable capacity of dry type with flexible walls, e.g. bellows

Abstract

An exemplary method and system is disclosed that facilitate the integration of multiplexed single-cell impedance cytometry in a high throughput format, which can be deployed upstream from microfluidic sample preparation and/or downstream to microfluidic cell separation. In exemplary method and system may employ impedance-based quantification of cell electrophysiology on the same microfluidic chip (i.e., “on-chip”) to provide distinguishing phenotypic information on the sample, without the need for additional sample handling, preparation or dilution steps as would be needed for other flow cytometry techniques.

IPC Classes  ?

• G01N 15/10 - Investigating individual particles
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 15/1031 - Investigating individual particles by measuring electrical or magnetic effects

Abstract

A system for increasing power capture comprising a turbine having a rotor, a generator having a rated power limit, and an energy storage system, wherein the rotor generates a super-rated power above the rated power limit of the generator and the super-rated power is stored in the energy storage system before the generator converts the super-rated power into electric power.

IPC Classes  ?

• H02K 7/18 - Structural association of electric generators with mechanical driving motors, e.g.with turbines
• H02P 9/02 - Arrangements for controlling electric generators for the purpose of obtaining a desired output Details

Abstract

A method for treatment of a patient suffering from a cancer, an autoimmune disease, an infection, a neurodegenerative disease or any combination thereof is disclosed. Compositions and uses are also disclosed. The method includes providing fresh immune effector cells (IECs) armed with one or more multispecific antibodies, wherein the multispecific antibodies are bound to the fresh IECs; and administering an effective amount of a composition of cells to the patient, wherein the composition of cells comprises the multispecific antibody bound fresh IECs. The fresh IECs cab comprise a cell selected from the group consisting of peripheral blood mononuclear cells (PBMC), antigen-presenting cells. T cells (optionally fresh Bi Ab armed T cells (FBATs)). NK cells, monocytes, polymorphonuclear neutrophils (PMNs), and any combination thereof. Providing the fresh IECs can comprise isolating fresh IECs from the patient. Arming fresh IECs can be accomplished with one or more multispecific antibodies, wherein the multispecific antibodies are bound to the fresh IECs.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/0787 - Granulocytes, e.g. basophils, eosinophils, neutrophils or mast cells

Abstract

A method of measuring thermal conductivity of a material includes aiming a modulated pump laser beam having a modulation frequency low enough to induce a cyclical steady-state temperature rise having “on” and “off” state at a spot of a material, aiming a CW probe laser beam at the spot and generating a reflected probe beam reflected from the spot on the material, the reflected probe beam having a magnitude of a reflectance signal as a function of the temperature of the material and being periodic corresponding to the cyclical temperature rise, measuring the pump power difference and the reflectance signal magnitude difference between the “on” and “off” states, and calculating the thermal conductivity by fitting the measured power difference and the measured reflectance signal magnitude difference to a thermal model which is a function of a thermal conductivity of the material relating the heat flux to the temperature rise.

IPC Classes  ?

• G01N 25/18 - Investigating or analysing materials by the use of thermal means by investigating thermal conductivity
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• G01N 21/55 - Specular reflectivity
• G01N 25/20 - Investigating or analysing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity

Abstract

Sulfonyl-triazole compounds and related sulfonyl-heterocycle compounds are described. The compounds can form covalent adducts with reactive nucleophilic amino acid residues, e.g., reactive tyrosines and reactive lysines, in kinases to form modified kinases and/or alter the biological activity of the kinases. Kinases targetable by the compounds include cyclin-dependent kinase 2 (CDK2), diacylglycerol kinases (DGKs), and phosphofructokinase (PFK). Pharmaceutical compositions including the compounds and methods of inhibiting kinases are also described.

IPC Classes  ?

• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 487/04 - Ortho-condensed systems

Abstract

A wireless charging station installed on the seafloor is equipped with multiple wireless transmitter coils and powered by a large-capacity lithium-battery-based energy storage system (ESS). Correspondingly, small-size wireless receiver coils are installed inside underwater robots and vehicles. When the battery is low in the underwater devices, the robots and vehicles automatically swim to the charging station and land in a specific charging region. After identifying the robots and vehicles, the wireless charging station can automatically start a wireless charging operation.

IPC Classes  ?

• H02J 50/12 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling of the resonant type
• B60L 53/126 - Methods for pairing a vehicle and a charging station, e.g. establishing a one-to-one relation between a wireless power transmitter and a wireless power receiver

Abstract

Embodiments disclosed herein provide methods of making polymer-metal organic framework-gels (polymer-MOF-gels), the method comprising forming a metal solution comprising a metal salt, an acid, and a first solvent, and forming a product mixture comprising the metal solution, a polymer, and a carboxylic acid linker to produce the polymer-MOF-gel. Embodiments disclosed herein provide polymer-MOF-gels comprising a polymer and a metal organic framework (MOF) having pores, wherein at least a portion of the polymer is entrapped in the pores of the MOF.

IPC Classes  ?

• B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/32 - Impregnating or coating

Abstract

Provided herein is a fluorescence-based assay that reports on the accessibility of molecules to the surface of bacteria.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

Characterizing the latent heat of fusion of a sample material can involve irradiating the sample material with laser light generated by a first laser, which includes elevating the temperature of the material to induce a phase transition between solid and liquid states. The method can also include measuring a property of the sample material during thermal arrests, which occur when the material transitions between these states. The composition of the sample material can be determined, e.g., by utilizing values corresponding to the amount of energy delivered to the sample material by the laser light and the properties measured during the thermal arrests.

IPC Classes  ?

• C09K 5/06 - Materials undergoing a change of physical state when used the change of state being from liquid to solid or vice-versa
• G05B 19/02 - Programme-control systems electric
• G01J 5/00 - Radiation pyrometry, e.g. infrared or optical thermometry

Abstract

CryptosporidiumCryptosporidium infection, comprising one or more cryptosporidial antigens selected from Gp900, CpMuc8, CpSMP1, CpCCDC, and/or CpCorA, optionally Cp23 and/or Cp17.

IPC Classes  ?

• A61K 39/012 - Coccidia antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• C07K 16/20 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa

Abstract

A computer implemented method of training a deep learning convolutional neural network (CNN) to correct output magnetic resonance images includes acquiring magnetic resonance image (MRI) data for a region of interest of a subject and saving the MRI data in frames of k-space data. The method includes calculating ground truth image data from the frames k-space data. The method includes corrupting the k-space data with real noise additions into the lines of the k-space data and saving in computer memory, training pairs a ground truth frame and a corrupted frame with real noise additions. By applying the training pairs to a U-Net convolutional neural network, the method trains the U-Net to adjust output images by correcting the output images for the real noise additions.

IPC Classes  ?

• G06T 5/60 - Image enhancement or restoration using machine learning, e.g. neural networks
• G06T 5/70 - DenoisingSmoothing
• G06T 11/00 - 2D [Two Dimensional] image generation

Abstract

Provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated with viral infections in subjects, which in some embodiments can include administering to the subject an effective amount of a PTP4A3 inhibitor. In some embodiments, the disease, disorder, and/or condition is characterized by lung damage, ALI, ARDS, or any combination thereof. Also provided are methods for reducing or inhibiting virus-induced alveolar inflammation and/or damage, methods for reducing or inhibiting induction of inflammatory cytokines and/or chemokines in subjects, methods for reducing or inhibiting pulmonary diseases, disorders, and/or conditions associated with viral infections, or pulmonary damage resulting therefrom, methods for preventing and/or treating chemical damage to lungs, uses of PTP4A3 inhibitors in the presently disclosed methods.

IPC Classes  ?

• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61P 31/14 - Antivirals for RNA viruses
• A61P 39/00 - General protective or antinoxious agents

Abstract

A circuit implementation for on-chip real-time resonance frequency measurement and feedback control may be used to provide improved selective particle trapping. The circuit may be based on monitoring current drawn from the amplifier used to stimulate the piezo transducer, as the high impedance measurement sensitivity in this mode does not lower the power available for stimulation of the piezo transducer. The enhanced level of control of acoustic trapping using this current mode may be used for various localized channel perturbations, including drift, wash steps and buffer swaps, as well as for selective sperm cell trapping from a heterogeneous sample that includes lysed epithelial cells.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction

Abstract

Various examples are provided related to single or multisensory stimulation to improve patient experience and tolerability during awake or minimal sedation procedures. In one example, a system includes a vibratory array including first and second vibration sources coupled to an adjustable support structure for positioning about a procedure site; and a control unit communicatively coupled to the first and second vibration sources. Vibrational frequency of the vibration sources is controlled by the control unit. The multisensory system can also include an AR headset and a computing device to provide content on the AR headset. In another example, a method for stimulation during an awake or minimal sedation procedure includes providing a vibratory array; positioning the vibration sources on an individual about a procedure site; and adjusting the vibrational frequency of the vibration sources based upon stress, pain, discomfort, and/or anxiety level of the individual during the procedure.

IPC Classes  ?

• A61H 23/02 - Percussion or vibration massage, e.g. using supersonic vibrationSuction-vibration massageMassage with moving diaphragms with electric or magnetic drive

Abstract

Provided herein are compositions and methods of hyaluronan biosynthesis, secretion and length control.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins

Abstract

Disclosed herein are systems and methods for reliable and verifiable tracking and reporting of value chain data. In one respect, a management system is provided for a value chain platform, configured to: verify digital certificates confirming suppliers' compliance with emissions tracking criteria of the value chain platform; deploy at least one smart contract on a permissioned blockchain of the value chain platform, the smart contract configured to process one or more emissions tokens of upstream suppliers plus emissions data of a current supplier, to automatically mint a new emissions token representing a combination of the two; and generate a report of cumulative emissions for a given product of the value chain, based on the new emissions token.

IPC Classes  ?

• G06Q 10/10 - Office automationTime management

Abstract

XUXUXmXmUUU.

IPC Classes  ?

• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• G06N 20/00 - Machine learning
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

A device may include an electrochemical storage device comprising an electrode having materials with targeted stoichiometry of TiNb2O7 (TNO), MoO2 (MO), or mixtures of TNO and MO.

IPC Classes  ?

• H01M 4/13 - Electrodes for accumulators with non-aqueous electrolyte, e.g. for lithium-accumulatorsProcesses of manufacture thereof
• H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/48 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides
• H01M 4/139 - Processes of manufacture
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy

Abstract

A device may include an electrochemical storage device comprising a two electroactive materials, where one of the materials is in much lower weight fraction and functions to facilitate electronic conductions through the electrode matrix. One system includes layered oxide LiNi0.80Co0.15A10.05O2 (NCA) at least partially coated with a coating with stoichiometry LixCoyOz (LCO).

IPC Classes  ?

• H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/46 - Alloys based on magnesium or aluminium
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 4/64 - Carriers or collectors
• H01M 4/66 - Selection of materials
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/38 - Construction or manufacture
• H01M 4/139 - Processes of manufacture
• H01M 10/05 - Accumulators with non-aqueous electrolyte

Abstract

A device may include an electrochemical storage device comprising LiNi0.80Co0.15Al0.05O2 (NCA), LiCoO2 (LCO), or a blend thereof.

IPC Classes  ?

• H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/46 - Alloys based on magnesium or aluminium
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 4/64 - Carriers or collectors
• H01M 4/66 - Selection of materials
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/38 - Construction or manufacture
• H01M 4/139 - Processes of manufacture
• H01M 10/05 - Accumulators with non-aqueous electrolyte

Abstract

An exemplary method and system is disclosed that facilitate the integration of on-chip impedance sensors and measurement circuitries, e.g., in characterizing internal microfluidic structures and/or in cell or particle cytometry, for quantifying the impedance/frequency response of microfluidic device under the same, or similar, conditions used for particle manipulation. In some embodiments, the exemplary method and system employs a circuit configured for automated determination and quantification of parasitic voltage drops during AC electrokinetic particle manipulation, without the need to use valuable biological samples or model particles. The determined impedance response can be used to assess efficacy of the microfluidic device geometry as well as to provide control signals to inform downstream cell separation decisions.

IPC Classes  ?

• G01N 15/1031 - Investigating individual particles by measuring electrical or magnetic effects
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
• G01N 33/483 - Physical analysis of biological material
• G01R 27/16 - Measuring impedance of element or network through which a current is passing from another source, e.g. cable, power line

Abstract

Methods, systems, and computer readable media for performing FDG positron emission tomography (PET) quantification, segmentation, and classification of abnormalities are disclosed. One method includes receiving a plurality of magnetic resonance (MR) images corresponding to a target site of a subject and generating three dimensional (3D) area masks of abnormality volumes from the plurality of MR images. The method further includes segmenting the 3D area masks into one or more individual seed images for each of the abnormality volumes and overlaying the one or more individual seed images onto co-registered parametric PET maps to generate kinetic rate parameters for each of the abnormality volumes. The method also includes utilizing the kinetic rate parameters to train a logistic regression engine to predict a target site condition assessment based on a classification of the abnormality volumes.

IPC Classes  ?

• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• A61B 6/03 - Computed tomography [CT]
• A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
• G01R 33/48 - NMR imaging systems
• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation
• G06T 7/30 - Determination of transform parameters for the alignment of images, i.e. image registration
• G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
• G06V 10/766 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using regression, e.g. by projecting features on hyperplanes

Abstract

Provided are stable hydrogels systems with polymeric fibers and method of preparation thereof. Advantageously, the present hydrogel systems can have improved stability without the need of covalent crosslinking between the fibers. Due to their unique mechanical properties and stability, the present hydrogel systems may be useful for a wide variety of applications, including 3D printing, tissue engineering, regenerative medicine, drug delivery, and implantation.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• B33Y 10/00 - Processes of additive manufacturing

Abstract

Provided herein is a drug screening method as well as an automatic screening of biopsy tissue to identify and grade cancer progression without any labeling.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 21/64 - FluorescencePhosphorescence
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Described herein are systems, methods, and computer-readable medium for magnetic resonance (MR) based thermometry. A method for magnetic resonance based thermometry includes: acquiring, by a variable flip-angle T1 mapping sequence, MR data in an area of interest of a subject that is heated by the application of focused ultrasound (FUS) to the brain of the subject, where the MR data includes T1 values over time, and where the acquisition of the MR data includes applying an accelerated three-dimensional ultra-short spiral acquisition sequence with a nonselective excitation pulse; tracking changes in proton resonance frequency and determining, based at least in part on a mathematical relationship established by T1 mapping thermometry, a temperature change in the area of interest over time, and where the temperature change is caused at least in part by a change in the applied FUS.

IPC Classes  ?

• G01R 33/48 - NMR imaging systems
• G01R 33/50 - NMR imaging systems based on the determination of relaxation times

Abstract

Disclosed herein are peptides and peptidomimetics that inhibit the progression of prostate cancer by up-regulating FLRT3. Also disclosed are methods for treating an FLRT3-attenuated cancer in a subject that involve administering to the subject the disclosed polypeptide or peptidomimetic or a polynucleotide encoding the disclosed peptide.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

Provided herein are methods for treating lung ischemia-reperfusion injury (IRI) by targeting the purinergic P2Y2 receptor (P2Y2R) and other members of the Panx1-P2Y2R-TRPV4 signaling pathway.

IPC Classes  ?

• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Abstract

A composition and method for a microtexture hydrophobic or superhydrophobic coating. The microtexture coating includes a coating layer disposed on a substrate with hydrophobic or superhydrophobic particles dispersed on top of or partially embedded in the coating layer to form an outer layer. The outer layer exhibits water repellant properties. Use of the microtexture coating permits large scale, durable hydrophobic or superhydrophobic coating applications. The microtexture coating is a useful for application on wind turbines, airplanes, solar panels, windows, or cooling systems.

IPC Classes  ?

• B05D 5/08 - Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures to obtain an anti-friction or anti-adhesive surface
• B05D 1/12 - Applying particulate materials
• C09D 5/03 - Powdery paints
• C09D 7/40 - Additives
• C09D 7/65 - Additives macromolecular
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures

Abstract

The present disclosure provides techniques for characterizing an electromagnetic field. One such method comprises exposing atoms in a vapor cell to an unknown electromagnetic field and a reference electromagnetic field, where the atoms are in a gas state and contained in a vacuum enclosure; directing a probe laser beam and a coupling laser beam into the vapor cell, the probe laser beam enabling the atoms within the vapor cell to transition from a ground state to an excited state, the coupling laser beam enabling the atoms within the vapor cell to transition from the excited state to a Rydberg state; and characterizing the unknown electromagnetic field based at least in part on a transmission spectrum of the probe laser beam after it has passed through the vapor cell and the atoms have interacted with the unknown electromagnetic field and the reference electromagnetic field.

IPC Classes  ?

• G01R 29/08 - Measuring electromagnetic field characteristics
• G01R 35/00 - Testing or calibrating of apparatus covered by the other groups of this subclass
• G01R 33/02 - Measuring direction or magnitude of magnetic fields or magnetic flux

Abstract

Provided are sulfonyl triazole compounds as well as compositions thereof and methods for using the same for modulating the formation of ribonucleoprotein granules (RNPGs), treating symptoms of diseases or infections in subjects including but not limited to viral infections, cancers and/or tumors, and/or neurological diseases. In some embodiments, the sulfonyl triazole compounds have the structure of Formula (I) as defined herein.

IPC Classes  ?

• C07D 249/04 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles
• C07D 249/08 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/4196 - 1,2,4-Triazoles
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 31/12 - Antivirals
• A61P 35/00 - Antineoplastic agents

Abstract

In one aspect, the disclosure relates to nanoclusters comprising cores comprising self-assembled unimolecular nanoparticles and biomimetic membrane coatings surrounding the cores, methods of making the same, and methods of treating and preventing restenosis using same. In some embodiments, the nanoclusters can contain an anti-restenotic drug. In one embodiment, the polymers and/or copolymers of the unimolecular nanoparticles can contain a hydrophobic group such as, for example, a phenylboronic ester. In a further embodiment, the biomimetic membrane can localize the nanoclusters at sites of vascular damage, at which time reactive oxygen species (ROS) at the sites of vascular damage cleave the hydrophobic groups from the polymers and/or copolymers, increasing hydrophilicity of the polymers and/or copolymers and allowing for greater tissue penetration of the de-clustered nanoclusters and nanoparticles.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers

Abstract

Compositions and methods for modifying the production levels of alkaloids in plants are provided. Alkaloid production can be genetically controlled by modulating the transcriptional activation of PMT genes mediated by members of the ERF family and/or Myc family of transcription factors. Novel nucleotide sequences encoding the Myc family of transcription factors are also provided.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

Disclosed is a method of modulating DNA damage response (DDR) signaling in a cell in which the modulating of DDR signaling is desired. In representative embodiments, the method comprises administering to the cell an effective amount of a substance capable of modulating cyclic GMP-AMP synthase-cyclic guanosine monophosphate-adenosine monophosphate (cGAS-cGAMP) pathway activity in the cell to thereby modulate DDR signaling in the cell.

IPC Classes  ?

• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

A system and method to determine characteristics of surgical related items and procedure related items present for use in the perioperative period. The system and method may apply computer vision for determining status and tracking of the surgical related items and procedure related items, as well as related clinical, logistical and operational events in the perioperative period. The system and method provides for an intuitive, automated, and transparent tracking of sterile surgical items (SSI) such as single-use, sterile surgical supplies (SUSSS) and sterile surgical instruments, and quantification of SSI waste. In doing so, the system and method empowers administrators to reduce costs and surgeons to demonstrate usage of important equipment. The system and method removes the guesswork from monitoring and minimizing SSI waste and puts the emphasis on necessity and efficiency.

IPC Classes  ?

• G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades

Abstract

Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.

IPC Classes  ?

• A61L 24/06 - Surgical adhesives or cementsAdhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• A61B 8/08 - Clinical applications
• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
• A61B 17/34 - TrocarsPuncturing needles
• A61B 17/42 - Gynaecological or obstetrical instruments or methods
• A61F 6/22 - Vas deferens occludersFallopian occluders implantable in tubes
• A61K 49/22 - Echographic preparationsUltrasound imaging preparations
• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances

Abstract

A surgical incision apparatus and method for puncturing a cutaneous layer of a subject for providing guided access to a subcutaneous organ or subcutaneous cavity (or specified target region) of the subject. The apparatus may include a retention body configured for securing a cutting tool therein and a housing configured for receiving the retention body. The apparatus includes a guidewire holder member configured for receiving a guidewire therein and aligning with the guidewire to allow the cutting tool to travel along the guidewire. The retention body is configured to be movably attached relative to the housing to allow the retention body and cutting tool to advance toward the subject to a deployed position, and subsequently withdraw to a retracted position.

IPC Classes  ?

• A61B 17/3211 - Surgical scalpels or knivesAccessories therefor
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/32 - Surgical cutting instruments

Abstract

The present disclosure provides SPNS2 inhibitor compounds according to Formula I: where T, U, V, W, X, R1, R2, and m are defined herein. The present disclosure also provides pharmaceutically acceptable salts, and/or tautomers of Formula I compounds as described in the disclosure. Also provided are their methods of use in therapy, such as in diseases for which immunomodulation and/or anti-fibrotic activity is indicated.

IPC Classes  ?

• C07D 213/65 - One oxygen atom attached in position 3 or 5
• C07D 235/16 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 295/195 - Radicals derived from nitrogen analogues of carboxylic acids
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 487/08 - Bridged systems
• C07D 487/10 - Spiro-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61P 11/06 - Antiasthmatics
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin